Cargando…
表皮生长因子受体突变细胞系H1650耐药机制探讨
BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) overexpression and mutations were existed in more than 40% of the lung cancer, and it's the one of molecular targets in clinical treatment. But the EGFR tyrosine kinase inhibitors (TKI)-resistance is becoming a challenging clinic...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000043/ https://www.ncbi.nlm.nih.gov/pubmed/23249714 http://dx.doi.org/10.3779/j.issn.1009-3419.2012.12.02 |